- Home
- OTLK vs ARAI Comparison
OTLK vs ARAI Comparison
Compare OTLK & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | ARAI |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 32.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | ARAI |
|---|---|---|
| Price | $0.78 | $0.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 23.7M | 1.1M |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | $800.66 |
| Revenue Next Year | $173.23 | $650.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.50 |
| 52 Week High | $3.39 | $15.50 |
Technical Indicators
Market Signals| Indicator | OTLK | ARAI |
|---|---|---|
| Relative Strength Index (RSI) | 74.55 | 31.21 |
| Support Level | $0.42 | N/A |
| Resistance Level | $1.18 | $0.78 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 74.57 | 19.34 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ARAI Arrive AI Inc.
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.